Cocrystal Pharma

Cocrystal Pharma EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Cocrystal Pharma (COCP) as of Nov 4, 2026 is -9.02 M USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -17.88 M USD — a change of -49.55% (higher).

EBITDA

-9.02 MUSD

YoY

-49.55%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Cocrystal Pharma is 2025 -9.02 M USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Cocrystal Pharma was 2024 -17.88 M USD. It decreases by -49.55% higher compared to the previous year.

The Cocrystal Pharma EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
-62.92 M USD
Jan 1, 2019
-48.41 M USD
Jan 1, 2020
-9.64 M USD
Jan 1, 2021
-14.22 M USD
Jan 1, 2022
-38.84 M USD
Jan 1, 2023
-18.56 M USD
Jan 1, 2024
-17.88 M USD
Jan 1, 2025
-9.02 M USD
The Cocrystal Pharma EBITDA history
YEAREBITDAYoY
-9.02 MUSD-49.55%
-17.88 MUSD-3.67%
-18.56 MUSD-52.21%
-38.84 MUSD+173.08%
-14.22 MUSD+47.52%
-9.64 MUSD-80.09%
-48.41 MUSD-23.07%
-62.92 MUSD+661.61%
-8.26 MUSD-92.19%
-105.82 MUSD+96.15%
-53.95 MUSD+830.30%
-5.80 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cocrystal Pharma Stock analysis

What does Cocrystal Pharma do? Cocrystal Pharma Inc, based in Bothell, Washington, is a biotechnology company focused on developing novel antiviral therapeutics. The company specializes in discovering and commercializing treatments for serious viral diseases, including hepatitis C, influenza, and norovirus, using computational methods to design drug candidates. Listed on 12 March 2018, it currently employs 10 full-time staff. Cocrystal Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cocrystal Pharma stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Cocrystal Pharma is -9.02 M USD in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Cocrystal Pharma changed from -17.88 M USD to -9.02 M USD, representing a -49.55% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Cocrystal Pharma since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Cocrystal Pharma historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Cocrystal Pharma

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Cocrystal Pharma